Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing

Remy B. Verheijen, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema, Neeltje Steeghs

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

69 Citaten (Scopus)


Pazopanib is an inhibitor of the vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor and stem cell receptor c-Kit, and has been approved for the treatment of renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib are complex and are characterized by pH-dependent solubility, large interpatient variability and low, non-linear and time-dependent bioavailability. Exposure to pazopanib is increased by both food and coadministration of ketoconazole, but drastically reduced by proton pump inhibitors. Studies have demonstrated relationships between systemic exposure to pazopanib and toxicity, such as hypertension. Furthermore, a strong relationship between pazopanib trough level ≥20 mg/L and both tumor shrinkage and progression-free survival has been established. At the currently approved daily dose of 800 mg, approximately 20% of patients do not reach this threshold and may be at risk of suboptimal treatment. As a result of this, clinical trials have explored individualized pazopanib dosing, which demonstrate the safety and feasibility of individualized pazopanib dosing based on trough levels. In summary, we provide an overview of the complex pharmacokinetic and pharmacodynamic profiles of pazopanib and, based on the available data, we propose optimized dosing strategies.

Originele taal-2Engels
Pagina's (van-tot)987-997
Aantal pagina's11
TijdschriftClinical Pharmacokinetics
Nummer van het tijdschrift9
StatusGepubliceerd - 1 sep. 2017
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing'. Samen vormen ze een unieke vingerafdruk.

Citeer dit